Full-Time
Director of Product Management
Biopharmaceutical Manufacturing
Posted on 7/11/2025
ABEC
501-1,000 employees
Integrated bioprocessing equipment and services.
No salary listed
Bethlehem, PA, USA
In Person
 Product (1) |
|---|
- Bachelor’s degree in a relevant field (e.g., Life Sciences, Engineering, Biotechnology)
- 10+ years of experience in product management, product development, or marketing within the biopharmaceutical manufacturing industry or a related sector
- Proven track record of launching successful products and driving growth in a B2B environment
- Experience leading cross-functional teams and managing complex projects
- Strong understanding of biopharmaceutical manufacturing processes, industry standards, and regulatory requirements
- Working technical knowledge of bioprocess equipment (fermenters, bioreactors, filtration, chromatography, CIP, Single Use Systems, etc.)
- Strong analytical abilities and attention to detail
- Excellent verbal and written communication skills
- Ability to effectively drive activity in a matrixed organization
- Ability to travel when necessary
- Define and own the product roadmap aligned with company strategy and market opportunities
- Conduct market research, competitive analysis, and customer feedback assessments to identify unmet needs and drive product innovation
- Assess product competitiveness in the marketplace and perform Strengths/ Weaknesses/ Opportunities/ Threats (SWOT) analyses for the product line
- Prioritize product features and development projects based on business value, customer needs, and resource availability
- Manage the product lifecycle from concept to end-of-life, ensuring alignment with company objectives
- Establish and track KPIs to measure product performance, customer satisfaction, and market success
- Evaluate and prioritize potential product changes and improvements based on return on investment
- Plan and drive product cost reduction by analyzing costs in materials, design, manufacturing, testing, and QA
- Lead a team of engineers and subject matter experts to implement product improvements
- Set priorities, develop plans, and manage execution
- Evaluate, develop, and mentor team personnel while addressing resource needs
- Collaborate with other ABEC functions to resolve product-related issues and support sales, projects, and services
- Train ABEC functions on product design and functionality
- Educate business development teams on product features and benefits
- Provide product capability and definition support to Sales and Applications teams during the sales process
- Lead cross-functional teams, including R&D, engineering, and regulatory affairs, to design and develop innovative solutions for biopharmaceutical manufacturing
- Collaborate with regulatory and compliance teams to ensure product adherence to industry standards (e.g., GMP, FDA, EMA guidelines)
- Foster partnerships with key stakeholders, including suppliers and technology providers, to enhance product offerings
- Oversee the development and validation of scalable manufacturing processes for new products
- Drive innovation by staying informed about industry trends, emerging technologies, and customer challenges
- Develop and execute go-to-market strategies, ensuring successful product launches and sustained market adoption
- Craft compelling value propositions, product positioning, and messaging tailored to the biopharmaceutical audience
- Partner with the sales team to create sales enablement tools, technical documentation, and training materials
- Represent the company at industry events, conferences, and webinars to promote thought leadership and product awareness
- Monitor and analyze market performance, adjusting strategies as needed to maximize ROI
- Support additional company needs as assigned
- Advanced degree (MBA, Ph.D., or Master’s) in a related field preferred
ABEC provides integrated biopharmaceutical manufacturing solutions and services. It supports vaccine and antibody production with bioprocess engineering, equipment maintenance, troubleshooting, and repairs, plus design and build of complete bioprocess lines. It offers customized single-use disposable containers, especially Custom Single Run (CSR) products, leveraging 45+ years of design experience. Its goal is to help clients scale manufacturing faster and at lower costs through in-house engineering, global capacity, and long-term partnerships.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Bethlehem, Pennsylvania
Founded
1974
Simplify's Take
What believers are saying
- ABEC's $11M Wilson, NC expansion boosts capacity starting April 2023.
- 5-year warranty on CSR single-use systems enhances client confidence.
- ATB bioreactor launched March 31, 2025, advances ATMP cell therapy production.
What critics are saying
- GOOD Meat counterclaims breach contract, draining resources since March 2023.
- Thermo Fisher undercuts with 0.2L-2000L perfusion systems capturing ATMP clients.
- Sartorius delivers 30% faster single-use containers via German cleanrooms.
What makes ABEC unique
- ABEC's CSR bioreactors enable seamless scale-up from 200L to production matching stainless steel performance.
- ABEC offers largest global biopharma manufacturing with 367,500 ft² and ISO-7 cleanrooms.
- ABEC delivers customized single-use systems exclusively for production-scale bioprocessing over 45 years.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Holidays
Paid Vacation
Medical, dental and vision insurance
Company paid life insurance
401(k) Company Match
401(k) Retirement Plan
College tuition benefit program
Employee Referral Program
Company News
ABEC, a global leader in engineered solutions and services for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB(TM), a revolutionary platform focused on transforming cell expansion for Advanced Therapy Medicinal Products (ATMPs).
Eat Just and its cultivated meat subsidiary GOOD Meat have reached an agreement in principle to settle their legal dispute* with bioreactor supplier ABEC, according to court documents, although the matter has not yet reached a final resolution.In a letter to Judge Wendy Beetlestone dated February 6, attorneys for both parties explained that they “have engaged in serious settlement negotiations over the past few months and have reached an agreement in principle regarding the framework for a settlement agreement and the material terms.“However, due to the complex nature of the claims, defenses, and counterclaims,” they added, “the parties require additional time to draft a binding agreement.”In a court order filed on February 7, Judge Beetlestone agreed to their request for the court to appoint a magistrate judge as settlement master to facilitate a final resolution, but rejected their request for a 30-day stay on the litigation and all case deadlines.Neither party has responded to a request for comment from AgFunderNews.What is the case about?The legal dispute began in March 2023 when ABEC filed a lawsuit accusing GOOD Meat of breach of contract by failing to pay its bills on time.According to ABEC, GOOD Meat owed $62,649,231.79 for work ABEC had already completed. Eat Just, in turn, claimed that ABEC had breached the terms of their contract.ABEC, which had been working with GOOD Meat on pilot cultivated chicken facilities in California and Singapore, signed an agreement with the startup in August 2021. Under the seven-year deal, ABEC would design, manufacture, install and commission multiple 250,000-liter vessels— “the largest known bioreactors for avian and mammalian cell culture”—for a large-scale facility in the US.Given “financing hurdles,” by November 2022, Eat Just/GOOD Meat “recommended the evaluation of a phased approach, creating five 125,000-L bioreactors instead of four 250,000-L bioreactors,” and the two started corresponding over amendments to their agreement.By March 2023, ABEC said it had had no choice but to take legal action over unpaid bills. Eat Just/GOOD Meat responded by filing a series of counterclaims, arguing that the parties never formally ratified amendments to their original agreement, and that ABEC had simply proceeded as if they had.Speaking to AgFunderNews last year, Eat Just founder and CEO Josh Tetrick said he was “not attempting to raise money for a large-scale cultivated meat facility right now” and was instead focusing on process development at the firm’s plant in Alameda, California, and working on new cell lines he claimed would enable more efficient large-scale production.*The case is ABEC, Inc. v. Eat Just, Inc
Cultivated meat startup GOOD Meat has upped the ante in its increasingly ugly legal dispute with bioreactor specialist ABEC over alleged nonpayment of bills. GOOD has filed a series of counterclaims alleging that ABEC breached the terms of their contract and that GOOD Meat is in fact the wronged party. The litigation began in March 2023 when ABEC filed a lawsuit accusing GOOD Meat (a wholly owned subsidiary of Eat Just) of breach of contract by failing to pay its bills on time. ABEC, which had been working with GOOD Meat on pilot cultivated chicken facilities in California and Singapore, signed an agreement with the startup in August 2021. Under the seven-year deal, ABEC would design, manufacture, install and commission multiple 250,000-liter vessels— “the largest known bioreactors for avian and mammalian cell culture”—for a large-scale facility in the US with the capacity to produce up to 30 million pounds of meat
Eat Just—like Beyond Meat—is often seen as a proxy for the broader alternative protein space, regarded by some as a visionary foodtech pioneer attempting to disrupt two vast addressable markets (meat, eggs) and by other less charitable observers as a “house of cards built on one individual’s ability to separate people from their money.”. Regardless of where you sit on this spectrum, says one foodtech investor we spoke to this week, it would be “pretty catastrophic” for the category if either of these loss-making firms were to crash and burn, so a lot is riding on their performance in the coming months. So how should we view Eat Just, and can Tetrick—”one of the best capital-raisers in the business“— raise the funds to take cultivated meat from a loss-making novelty to a commercially viable alternative to animal agriculture?
Malcolm joins KPC from ABEC Inc, where he led the development of their European Services Business and contributed to their global capital project expansion.